These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 2575229)
1. Stimulus properties of hallucinogenic phenalkylamines and related designer drugs: formulation of structure-activity relationships. Glennon RA NIDA Res Monogr; 1989; 94():43-67. PubMed ID: 2575229 [No Abstract] [Full Text] [Related]
2. Discriminative stimulus properties of hallucinogens and related designer drugs. Glennon RA NIDA Res Monogr; 1991; (116):25-44. PubMed ID: 1369672 [TBL] [Abstract][Full Text] [Related]
3. Phenylalkylamine stimulants, hallucinogens, and designer drugs. Glennon RA NIDA Res Monogr; 1990; 105():154-60. PubMed ID: 1678860 [TBL] [Abstract][Full Text] [Related]
4. Arylalkylamine drugs of abuse: an overview of drug discrimination studies. Glennon RA Pharmacol Biochem Behav; 1999 Oct; 64(2):251-6. PubMed ID: 10515299 [TBL] [Abstract][Full Text] [Related]
5. Clinical toxicology of newer recreational drugs. Hill SL; Thomas SH Clin Toxicol (Phila); 2011 Oct; 49(8):705-19. PubMed ID: 21970769 [TBL] [Abstract][Full Text] [Related]
6. [The development from drug to designer drug]. Askaa B; Horwitz H; Wøien VA; Høgberg LC; Jürgens G Ugeskr Laeger; 2014 Oct; 176(42):. PubMed ID: 25316367 [TBL] [Abstract][Full Text] [Related]
7. "Legal highs" - new players in the old drama. Zawilska JB Curr Drug Abuse Rev; 2011 Jun; 4(2):122-30. PubMed ID: 21711229 [TBL] [Abstract][Full Text] [Related]
8. 2C or not 2C: phenethylamine designer drug review. Dean BV; Stellpflug SJ; Burnett AM; Engebretsen KM J Med Toxicol; 2013 Jun; 9(2):172-8. PubMed ID: 23494844 [TBL] [Abstract][Full Text] [Related]
9. [Mechanism of action of psychotropic drugs]. Kanig K Hippokrates; 1974 May; 45(2):181-202. PubMed ID: 4152489 [No Abstract] [Full Text] [Related]
10. [Entactogen and designer drugs]. Naito H Chudoku Kenkyu; 2010 Mar; 23(1):3-15. PubMed ID: 20380315 [No Abstract] [Full Text] [Related]
11. Pharmacology and toxicology of amphetamine and related designer drugs. NIDA Res Monogr; 1989; 94():1-357. PubMed ID: 2514359 [No Abstract] [Full Text] [Related]
12. [Entactogen and designer drugs]. Shirakawa Y Chudoku Kenkyu; 2010 Mar; 23(1):2. PubMed ID: 20380314 [No Abstract] [Full Text] [Related]
13. Self-injection in baboons of amphetamines and related designer drugs. Sannerud CA; Brady JV; Griffiths RR NIDA Res Monogr; 1989; 94():30-42. PubMed ID: 2514366 [No Abstract] [Full Text] [Related]
14. Structure-activity relationships of the classic hallucinogens and their analogs. Jacob P; Shulgin AT NIDA Res Monogr; 1994; 146():74-91. PubMed ID: 8742795 [No Abstract] [Full Text] [Related]
15. [Pharmacology of addiction]. van Ree JM Ned Tijdschr Geneeskd; 1995 Dec; 139(50):2610-3. PubMed ID: 8544882 [No Abstract] [Full Text] [Related]
16. Structure-activity relationships of BDB and its monomethyl and dimethyl derivatives. Bronson ME; Jiang W; DeRuiter J; Clark CR Pharmacol Biochem Behav; 1995; 51(2-3):477-9. PubMed ID: 7667372 [TBL] [Abstract][Full Text] [Related]
18. Drugs and the mental state. Smith SE Nurs Times; 1967 Mar; 63(11):356-7. PubMed ID: 4381229 [No Abstract] [Full Text] [Related]
19. [Neurologic complications of drug addiction. General aspects. Complications caused by cannabis, designer drugs and volatile substances]. Farre Albaladejo M Arch Neurobiol (Madr); 1989; 52 Suppl 1():143-8. PubMed ID: 2700291 [TBL] [Abstract][Full Text] [Related]
20. Quantum chemical studies on drug actions. 3. Correlation of hallucinogenic and anti-serotonin activity of lysergic acid derivatives with quantum chemical data. Kumbar M; Sankar DV Res Commun Chem Pathol Pharmacol; 1973 Jul; 6(1):65-100. PubMed ID: 4734018 [No Abstract] [Full Text] [Related] [Next] [New Search]